FibroGen, Inc. to Present Data for Roxadustat (FG-4592), an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Oral Presentations at American Society of Nephrology - Kidney Week 2013

FibroGen, Inc. (FibroGen), today announced that two abstracts relating to roxadustat (FG-4592), a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD), have been accepted for oral presentations at the American Society of Nephrology (ASN) Kidney Week 2013.

Help employers find you! Check out all the jobs and post your resume.